文献速递肾小球疾病

IL-2/抗IL-2复合物通过扩增CD4+CD25+Foxp3+调节性T细胞改善狼疮肾炎

IL-2/anti-IL-2 complexes ameliorate lupus nephritis by expansion of CD4+CD25+Foxp3+ regulatory T cells.
PubMed 文献 · Kidney Int · 2016-12-01

在NZB/W F1狼疮倾向小鼠中,IL-2/抗IL-2复合物(IL-2C)可有效且持续扩增肾脏和脾脏的CD4+CD25+Foxp3+调节性T细胞,减少蛋白尿及急慢性肾脏病理损伤,改善肾功能和生存;抗CD25抗体清除Treg可消除其益处;与激素联合吗替麦考酚酯相比,IL-2C疗效相似或更优。

要点

  • IL-2C在NZB/W F1小鼠肾脏和脾脏持续扩增CD4+CD25+Foxp3+ Treg。
  • IL-2C减少蛋白尿、肾脏病理损伤,改善肾功能和生存。
  • 抗CD25清除Treg可消除IL-2C的益处。

核心结论

  • IL-2C通过扩增Treg保护狼疮倾向小鼠免于狼疮肾炎,可能具有治疗潜力。

研究设计与样本

  • 在NZB/W F1狼疮倾向小鼠中测试由IL-2与抗IL-2单克隆抗体(JES6-1)组成的复合物(IL-2C)能否通过扩增Treg改善狼疮肾炎。

主要发现

  • IL-2C治疗使NZB/W F1小鼠肾脏和脾脏的CD4+CD25+Foxp3+ Treg有效且持续扩增,并减少T细胞、B细胞和固有免疫细胞的肾脏浸润。
  • 与对照相比,IL-2C治疗小鼠蛋白尿减少,急性和慢性肾脏病理病变更少,肾功能和生存改善。
  • IL-2C显著减轻肾小球和肾小管损伤、血管炎评分及IgG和C3的肾脏沉积。
  • IL-2C治疗小鼠血清中抗dsDNA抗体和免疫球蛋白高水平及补体低水平等疾病活动标志物改善。
  • IL-2C降低肾脏TNF-α和IL-6表达,以及肾脏和脾脏中IFN-γ+CD4+和IL-17A+CD4+ T细胞频率。

关键数值与推荐

  • 抗CD25抗体清除Treg可消除IL-2C的有益效应。
  • 与激素联合吗替麦考酚酯相比,IL-2C治疗显示相似或更好的结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adoptive transfer of regulatory T cells (Tregs) can delay disease progression and reduce mortality in lupus-prone mice. Here, we tested whether complex (IL-2C) consisting of IL-2 and anti-IL-2 monoclonal antibody (JES6-1) ameliorates lupus nephritis by expanding Tregs as an alternative to problematic Treg infusion therapy. IL-2C treatment of NZB/W F1 mice induced an effective and sustained expansion of CD4+CD25+Foxp3+ Tregs in both the kidneys and spleen along with decreased renal infiltration of T cells, B cells, and innate immune cells. Compared with controls, mice treated with IL-2C showed reduced proteinuria and fewer acute and chronic renal pathological lesions with improved renal function and survival. IL-2C significantly attenuated glomerular and tubular injury, vasculitis scores, and renal deposition of IgG and C3. Disease activity markers, such as high levels of anti-dsDNA antibodies and immunoglobulin levels, and low levels of complement were improved in sera of IL-2C-treated mice. IL-2C treatment decreased renal expression of TNF-α and IL-6, and the frequencies of IFN-γ+CD4+ and IL-17A+CD4+ T cells in both the kidneys and spleen. Depletion of Tregs by anti-CD25 antibodies abrogated the beneficial effects of IL-2C. When compared with combination therapy of steroid and mycophenolate mofetil, IL-2C treatment showed similar or better outcomes. Thus, IL-2C protected lupus-prone mice against lupus nephritis by expanding Tregs. Hence, IL-2C could have therapeutic potential in lupus nephritis.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Yan JJ, Lee JG, Jang JY, et al. IL-2/anti-IL-2 complexes ameliorate lupus nephritis by expansion of CD4+CD25+Foxp3+ regulatory T cells. Kidney Int. 2016. PMID: 27914701. doi:10.1016/j.kint.2016.09.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。